Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

about

Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi-institutional retrospective study of 64 cases.Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.

P2860

Q44869966-71E6508E-E43E-4EDB-B030-B7C0840BCEEF Q47417940-F2A4EAA4-3511-471D-B0AB-26EC141BA4E6

P2860

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

Item

http://www.wikidata.org/entity/Q53084383

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

@en

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

@nl

type

Item

label

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

@en

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

@nl

prefLabel

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

@en

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

@nl

P1476

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

@en

P2093

D Prata

http://www.w3.org/2001/XMLSchema#string

G Barzon

http://www.w3.org/2001/XMLSchema#string

G Bettini

http://www.w3.org/2001/XMLSchema#string

M Dacasto

http://www.w3.org/2001/XMLSchema#string

M Giantin

http://www.w3.org/2001/XMLSchema#string

R M Lopparelli

http://www.w3.org/2001/XMLSchema#string

P2860

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis

Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.

Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.

Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia.

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.

Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline

Mast cell tumors in cats: clinical update and possible new treatment avenues.

Immunohistochemical characterization of feline mast cell tumors.

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.

P304

1051-1061

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VCO.12246

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Silvia Sabattini

P577

2016-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27278268

http://www.w3.org/2001/XMLSchema#string

P921

mast cells

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

about

P2860

P2860

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921